LIPOPROTEIN PARTICLE MEASUREMENT: HELENA LABORATORIES and MAYO CLINIC COLLABORATION

Wednesday, September 29, 6:00 - 7:30 p.m.
Hyatt Regency, Centennial Ballroom 4
Supported by Helena Laboratories

Overview

Dr. McConnell will discuss Lipoprotein particle measurement by immunofixation electrophoresis and Nuclear Magnetic Resonance Spectroscopy. This technique combines lipoprotein electrophoresis to separate the lipoprotein particles and subsequent immunofixation with anti-apoB antisera to stain and quantitate the lipoproteins. This method has been shown to be precise, linear, and well suited for routine clinical use. Dr. Jeffrey Meeusen will discuss the experience with Lipoprotein particle measurement at the Mayo Clinic, Cardiovascular Laboratory Medicine. Many commercially available lipoprotein subfractionation methods can differentiate between "large­ buoyant" and "small-dense" LDL (sdLDL). Despite a lack of guideline endorsement, clinicians routinely request LDL subfraction for ASCVD risk assessment. Following multiple physician inquiries regarding interpretation of conflicting interpretations for LDL cholesterol (LDL-C) and LDL size (LDL-s), we investigated associations between LDL-C and LDL-s as reported by NMR spectroscopy.

Outcomes

Attendees will be able to:

  • Describe lipoprotein particles that can be measured by immune electrophoresis and differentiate which lipoproteins can be individually measured by electrophoresis and Nuclear Magnetic Resonance (NMR) analysis.
  • Discuss the importance of determining Lp(a) separately from LDL and how Lp(a) affects traditional methods for measurement of LDL.
  • Describe the relative frequency of contradicting risk assessment in clinically reported LDL cholesterol, LDL size, and LDL particle number.

Moderator

Robert S. Galen, MD, MPH
Professor Emeritus
College of Public Health – University of Georgia
Athens, GA

Speaker

Joseph P. McConnell, PhD, DABCC
Senior Vice President of Laboratory Medicine
Aditxt Therapeutics, Inc.
Richmond, VA